عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

Saudi Electricity Company Targets Net Zero Emissions by 2050

SEC acknowledged its role in addressing climate change and achieving carbon neutrality despite its tremendous contributions to providing electric power - SPA
SEC acknowledged its role in addressing climate change and achieving carbon neutrality despite its tremendous contributions to providing electric power - SPA
TT
TT

Saudi Electricity Company Targets Net Zero Emissions by 2050

SEC acknowledged its role in addressing climate change and achieving carbon neutrality despite its tremendous contributions to providing electric power - SPA
SEC acknowledged its role in addressing climate change and achieving carbon neutrality despite its tremendous contributions to providing electric power - SPA

The Saudi Electricity Company (SEC), the largest producer, transmitter, and distributor of electrical energy in the Middle East and North Africa, announced that it seeks to reach net zero emissions by 2050 in line with the Kingdom of Saudi Arabia’s endeavor to reach carbon neutrality by 2060 through the circular carbon economy approach, SPA reported.

The announcement was made during a special event SEC organized Tuesday on the sidelines of the United Nations COP28 climate-change summit in Dubai, during which the company said that it has laid the foundation of environmental practices that seek to reduce emissions through projects to raise energy efficiency, as well as developing the electricity transmission network into a smart network, with clean energy, renewable energy stations, and the smart meter project.

In line with its endeavor to achieve carbon neutrality, SEC said it has signed seven agreements and MoUs with leading local and international companies, including one with the Net Zero Technology Center (NZTC) and global professional services company Accenture to enhance solutions that help reduce carbon emissions in Saudi Arabia and beyond.

The agreement, which is part of SEC’s endeavors toward environmental sustainability, seeks to leverage digital technologies and artificial intelligence (AI) to contribute to reducing carbon emissions.
Under the agreement, SEC will collaborate with its partners to develop and launch a Center of Excellence for Sustainability, with the goal of developing solutions to reduce carbon emissions.

The company will also work with its partners to promote national innovation and entrepreneurship and develop local competencies.

“This day marks a milestone in our journey towards a sustainable future, as the Saudi Electricity Company proudly collaborates with NZTC and Accenture to establish a Center of Excellence for Sustainability,” SEC stated in a press release.

The cooperation between SEC, NZTC, and Accenture “demonstrates the company’s ongoing commitment to achieving decarburization targets throughout the Middle East,” said the release.

Most Viewed

 
 
Varieties

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”